“At the ESMO Virtual Congress 2020, we look forward to sharing important new results including survival data for KEYTRUDA in esophageal cancer and long-term findings in lung cancer, melanoma, and head and neck cancer, as well as research from our expansive pipeline.” Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. “At Merck, we are focused on further improving long-term outcomes for more patients living with cancer, and this commitment is reflected in the breadth and diversity of our oncology research program,” said Dr. Additionally, new findings will be shared for three of Merck’s novel investigational candidates: vibostolimab (MK-7684), an anti-TIGIT antibody MK-4830, an antibody targeting ILT4 and MK-6482, an oral HIF-2α inhibitor. Pivotal Phase 3 data evaluating KEYTRUDA in combination with chemotherapy for the first-line treatment of patients with locally advanced or metastatic esophageal cancer from the KEYNOTE-590 trial (Abstract #LBA8) and LYNPARZA in patients with metastatic castration-resistant prostate cancer (mCRPC) from the PROfound trial (Abstract #610O) were selected for inclusion in ESMO Presidential Symposium sessions. Data spanning more than 15 types of cancer will be presented at the congress, with new findings from Merck’s portfolio of established medicines including KEYTRUDA, Merck’s anti-PD-1 therapy LENVIMA ® (lenvatinib, in collaboration with Eisai) and LYNPARZA (in collaboration with AstraZeneca). Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new data from its broad and diverse oncology development program will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 from Sept. Merck to Hold Virtual Investor Briefing to Discuss ESMO Highlights Pivotal Studies for KEYTRUDA ® (pembrolizumab) in Esophageal Cancer (KEYNOTE-590) and LYNPARZA ® (olaparib) in Prostate Cancer (PROfound) Selected for ESMO Presidential Symposium Sessionsįirst-Time Data for Three Investigational Candidates From Merck’s Diverse and Advancing Early Pipeline to be Presented
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |